NCT04040725View on ClinicalTrials.gov

Rogaratinib for BCG Refractory High Risk Non-Muscle Invasive Bladder Cancer With FGFR1/2 Overexpression

PHASE2WithdrawnINTERVENTIONAL

0

Timeline

Start Date

November 27, 2019

Primary Completion Date

November 27, 2019

Study Completion Date

November 27, 2019

Conditions

Bladder Cancer

Interventions

DRUG

Rogaratinib

Rogaratinib is an oral drug that inhibits FGFR. Mutations in FGFR help bladder cancer grow.

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

Bayer

INDUSTRY

lead

Dana-Farber Cancer Institute

OTHER